FDA Approves Jideytro (zidesamtinib) for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer

Дата публикации: 22-07-2026 20:07:04

London, UK July 22, 2026 -- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer	0	20.66	24-06-2026
2	FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)	0	17.02	25-06-2026
3	FDA Grants Traditional Approval to Retevmo (selpercatinib) for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors	0	8.58	14-07-2026
4	FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer	0	11.85	10-07-2026
5	U.S. FDA Approves Padcev plus Keytruda or Keytruda Qlex as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility	0	13.8	10-07-2026
6	FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma	0	30	14-10-2026
7	France bans ‘forever chemicals’ in consumer products, with a catch	0	0	20-02-2025
8	FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma	0	13.78	19-10-2026
9	FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection for the Treatment of Multiple Myeloma	0	12.93	10-07-2026
10	FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer	0	14.79	23-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 16.54. Источник: www.drugs.com.